Daniel Ermann, MD, discusses findings from a real-world study of first-line BTK inhibitors in older patients with chronic lymphocytic leukemia.
Back
Evaluating First-Line BTK Inhibitors in Real-World, Older Chronic Lymphocytic Leukemia
Daniel A. Ermann, MD, and colleagues shared real-world data on first-line BTK inhibitors in older patients with chronic lymphocytic leukemia.
Evaluating First-Line BTK Inhibitors in Real-World, Older Chronic Lymphocytic Leukemia
Episodes
All
All
First-line zanubrutinib improved real-world treatment duration, time to next treatment, and survival in older chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
5